This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacological Treatment In Osteoarthritis (FABIO)

This study has been completed.
Information provided by (Responsible Party):
WeiChing Lee, Maasstad Hospital Identifier:
First received: June 18, 2010
Last updated: April 10, 2015
Last verified: April 2015
The purpose of this study is to determine the efficacy of hydroxychloroquine in hand osteoarthritis.

Condition Intervention Phase
Osteoarthritis Drug: Hydroxychloroquine Drug: cellulose Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Pharmacological Treatment In Osteoarthritis

Resource links provided by NLM:

Further study details as provided by WeiChing Lee, Maasstad Hospital:

Primary Outcome Measures:
  • Pain intensity measured by 100 mm Visual Analog Scale (VAS) [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • Hand function measured by Arthritis Impact Measurement Scales 2 short form (AIMS2-SF) and Australian/Canadian Osteoarthritis Hand Index (AUSCAN) [ Time Frame: 6, 12 and 24 weeks ]
  • Pain intensity measured by 100 mm VAS [ Time Frame: 6, 12 weeks ]
  • Radiological progression measured by the anatomical lesion progression system from Verbruggen et al. [ Time Frame: 24 weeks ]

Enrollment: 200
Study Start Date: July 2010
Study Completion Date: September 2014
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: cellulose
capsule, 2 capsules QD for 24 weeks
Other Name: placebo
Experimental: Hydroxychloroquine Drug: Hydroxychloroquine
200 mg capsule, 2 capsules QD for 24 weeks.
Other Name: Plaquenil

Detailed Description:
Osteoarthritis is the most common joint disease, most frequently involving the hands, resulting in pain, stiffness and loss of hand function. At present, there is no option to prevent the onset or the progression of hand osteoarthritis (OA). It is believed that inflammation plays an important role in the pathogenesis of OA and that anti-inflammatory drugs might be an effective treatment for OA. Anti-malarial agents like chloroquine and hydroxychloroquine are potential anti-inflammatory drugs and hydroxychloroquine has already proven to be an effective suppressor of inflammation in rheumatoid arthritis. Several previous studies with hydroxychloroquine in hand OA also showed a possible effect on pain and inflammation, but these studies were mostly retrospective with a small number of patients. This is the first prospective, randomised, placebo-controlled study to determine the effect of hydroxychloroquine in hand osteoarthritis.

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 40 years
  • Primary hand OA according to the ACR classification
  • Heberden or Bouchard nodule or Kellgren-Lawrence grade 1, 2 or 3 changes in ≥ 2 symptomatic joints
  • Pain in the dominant hand ≥ 12 months
  • Use of an NSAID for ≥ 1 episode of pain
  • Written informed consent

Exclusion Criteria:

  • Secondary hand OA, e.g. haemochromatoses, rheumatoid arthritis, posttraumatic
  • Kellgren-Lawrence grade 4 OA
  • Use of hydroxychloroquine within 3 months before entering the study
  • Use of NSAIDs or corticosteroids within 7 days before entering the study
  • Retinopathy
  • Myasthenia gravis
  • Known allergy or hypersensitivity for hydroxychloroquine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01148043

Admiraal de Ruyter Hospital
Goes, Netherlands
Maasstad Hospital
Rotterdam, Netherlands, 3079DZ
Erasmus Medical Center
Rotterdam, Netherlands
Sint Franciscus Gasthuis
Rotterdam, Netherlands
Vlietland Hospital
Schiedam, Netherlands
ZorgSaam Zeeuws-Vlaanderen
Terneuzen, Netherlands
Sponsors and Collaborators
Maasstad Hospital
Principal Investigator: Natalja M Basoski, MD Maasstad Hospital
  More Information

Responsible Party: WeiChing Lee, pharmacist, Maasstad Hospital Identifier: NCT01148043     History of Changes
Other Study ID Numbers: NL32030.101.10
Study First Received: June 18, 2010
Last Updated: April 10, 2015

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents processed this record on June 27, 2017